Overview

Influence of Lipid Lowering on Impaired Coronary Flow

Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This study assess in patients with stable chest pain and coronary artery disease (CAD) determined by coronary CTA whether cholesterol lowering with regression of coronary adverse plaque characteristics is associated with recovery of impaired flow
Phase:
N/A
Details
Lead Sponsor:
Aarhus University Hospital
Collaborator:
HeartFlow, Inc.
Treatments:
Atorvastatin
Ezetimibe
Rosuvastatin Calcium